Leqembi for Alzheimer's: Understanding the New Treatment

Understanding Leqembi (lecanemab-irmb) for Alzheimer's Disease

Alzheimer's disease is a progressive neurological disorder that affects millions worldwide, impacting memory, thinking, and behavior. While there is currently no cure, advancements in medical science have led to new treatment options aimed at slowing its progression. One such groundbreaking medication is Leqembi, a prescription drug approved by the Food and Drug Administration (FDA) in 2023. This article provides a comprehensive overview of Leqembi, its uses, potential side effects, and what it means for individuals and families affected by Alzheimer's disease in India.

What is Leqembi?

Leqembi, with the active ingredient lecanemab-irmb, is a type of medication known as a monoclonal antibody. It is a biologic drug, meaning it is derived from living cells, distinguishing it from chemically synthesized drugs. Leqembi is specifically designed to treat Alzheimer's disease in adults who have mild cognitive impairment or mild dementia. It works by targeting and removing amyloid beta plaques, a protein that builds up in the brain and is a hallmark of Alzheimer's disease. By reducing these plaques, Leqembi aims to slow down the worsening of the disease, offering a potential way to preserve cognitive function for a longer period.

How Leqembi Works

Alzheimer's disease is characterized by complex changes in the brain, including the accumulation of amyloid beta proteins. These proteins can form plaques that disrupt communication between brain cells and lead to neuronal damage. Leqembi is engineered to specifically bind to these amyloid beta plaques, facilitating their removal from the brain. Clinical studies have shown that Leqembi can effectively reduce the burden of amyloid plaques in the brains of individuals with early-stage Alzheimer's. While it does not reverse the damage already done or cure the disease, slowing its progression can significantly improve the quality of life for patients and their caregivers, allowing them to maintain independence and engagement for longer.

Who is Leqembi For?

Leqembi is prescribed for adults diagnosed with early-stage Alzheimer's disease. This includes individuals experiencing mild cognitive impairment (MCI) or mild dementia. In these early stages, individuals may notice subtle changes in their memory and thinking abilities, such as occasional forgetfulness or difficulty finding words. However, they are generally still able to perform their daily activities. It is crucial for diagnosis to be confirmed by a healthcare professional who can assess the stage of the disease and determine if Leqembi is an appropriate treatment option. The medication is not intended for advanced stages of Alzheimer's disease.

Administration and Dosage

Leqembi is administered in two primary forms:

• Intravenous (IV) Infusion: Leqembi is available as a liquid solution that healthcare professionals administer as an intravenous infusion. This typically occurs once every two weeks. The infusion process requires a clinical setting and monitoring by medical staff.
• Subcutaneous Injection: Leqembi Iqlik is a prefilled autoinjector that allows for subcutaneous (under the skin) injection, also typically administered once every two weeks. This option may offer more convenience for some patients.

The specific dosage and administration schedule will be determined by the treating physician based on the individual's condition and response to treatment.

Potential Side Effects of Leqembi

Like all medications, Leqembi can cause side effects, ranging from mild to serious. It is important for patients and caregivers to be aware of these potential risks. Leqembi carries a boxed warning, the most serious type of warning issued by the FDA, highlighting the potential for serious side effects.

Common Side Effects:

• Infusion Reactions: These can occur during or shortly after the infusion and may include symptoms like dizziness, rash, nausea, vomiting, or fatigue.
• Headache: Some individuals may experience headaches.
• Injection Site Reactions: For the subcutaneous form, redness, swelling, or pain at the injection site may occur.

Serious Side Effects:

More serious side effects, though less common, require immediate medical attention. These can include:

• Amyloid-Related Imaging Abnormalities (ARIA): This is a significant concern with Leqembi and involves temporary swelling (ARIA-E) or microhemorrhages (ARIA-H) in the brain. Symptoms can include headache, confusion, dizziness, vision changes, nausea, and difficulty speaking. In severe cases, ARIA can lead to seizures or other neurological complications. Regular MRI scans are often used to monitor for ARIA.
• Severe Infusion Reactions: Difficulty breathing, fever, changes in blood pressure, or allergic reactions can occur.

The risk and severity of side effects can depend on various factors, including the individual's age, overall health, and other medications they may be taking. Your doctor will discuss these risks in detail and monitor you closely during treatment.

Leqembi Precautions and Warnings

Due to the potential for serious side effects, particularly ARIA, Leqembi requires careful monitoring. Patients undergoing treatment should:

• Inform their doctor immediately about any new or worsening symptoms, especially neurological changes.
• Undergo regular MRI scans as recommended by their physician to detect any signs of ARIA.
• Discuss all other medications and supplements they are taking with their doctor to avoid potential interactions.

It is also important to note that information on the long-term side effects of Leqembi is still being gathered, as it is a relatively new medication. Studies have so far involved treatment durations of up to 18 months, with no long-term side effects reported in those specific trials.

Cost and Accessibility in India

The cost of Leqembi can be a significant factor for patients and their families. As a biologic medication, it is generally expensive. The exact cost can vary depending on the treatment plan, pharmacy, and healthcare facility. For individuals in India considering Leqembi, it is advisable to:

• Discuss the cost and potential financial assistance programs with your doctor and pharmacist.
• Inquire about insurance coverage, as policies may vary.
• Explore any available patient support programs, such as the Eisai Patient Support program, which may offer assistance with medication costs.

Navigating the financial aspects of treatment is crucial, and open communication with healthcare providers is key.

When to Consult a Doctor

It is essential to consult a doctor if you or a loved one has been diagnosed with early-stage Alzheimer's disease. A neurologist or a specialist in dementia care can provide an accurate diagnosis and discuss all available treatment options, including Leqembi. If you are already undergoing treatment with Leqembi, it is vital to consult your doctor immediately if you experience any of the following:

• New or worsening headaches
• Confusion or disorientation
• Dizziness or balance problems
• Vision changes
• Nausea or vomiting
• Difficulty speaking or understanding speech
• Seizures
• Any signs of infusion reaction (fever, chills, rash, difficulty breathing)

Early detection and management of side effects are critical for safe and effective treatment.

The Future of Alzheimer's Treatment

Leqembi represents a significant step forward in the fight against Alzheimer's disease. While it is not a cure, its ability to slow disease progression offers hope and the potential for improved outcomes for many. As research continues and more data becomes available, our understanding of Alzheimer's and its treatments will undoubtedly evolve. For individuals and families in India, staying informed about advancements like Leqembi and maintaining open communication with healthcare providers are crucial steps in managing this challenging condition.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.